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ABSTRACT
Identification of Protein-Ligand Interaction Fingerprints (PLIF) has been performed as the rescoring strategy to
identify the best pose for the docked poses of indomethacin-(R)-α-ethyl-etanolamide (IMM) in the binding site of 
cyclooxygenase-1 (COX-1) from simulations using PLANTS molecular docking software version 1.2 (PLANTS1.2).
Instead of using the scoring functions included in the docking software, the strategy presented in this article used
external software called PyPLIF that could identify the interactions of the ligand to the amino acid residues in the
binding pocket and presents them as binary bitstrings, which subsequently were compared to the interaction
bitstrings of the co-crystal ligand pose. The results show that PyPLIF-assisted redocking strategy could select the
correct pose much better compared to the pose selection without rescoring. Out of 1000 iterative attempts, PyPLIF-
assisted redocking simulations could identify 971 correct poses (more than 95%), while the redocking simulations
without PyPLIF could only identify 500 correct poses (50%).These works have also provided us with the initial step
of the construction of a valid Structure-Based Virtual Screening (SBVS) protocol to identify COX-1 inhibitors.
Keywords: PyPLIF; rescoring; Structure-Based Virtual Screening (SBVS); molecular docking
ABSTRAK
Telah dilakukan identifikasi sidik jari interaksi antara ligan dan protein sebagai strategi penskoran ulang guna
memilih posisi terbaik hasil penambatan molekuler ulang senyawa ko-kristal indomethacin-(R)-α-ethyl-etanolamide 
(IMM) ke dalam binding site siklooksigenase-2 (COX-1) luaran dari penggunaan aplikasi penambatan molekuler
PLANTS versi 1.2 (PLANTS1.2). Sebagai pengganti penggunaan fungsi penskoran bawaan asli dari aplikasi
penambatan molekuler PLANTS1.2, digunakanlah aplikasi eksternal bernama PyPLIF yang mampu mengidentifikasi
sidik jari interaksi antara ligan dengan residu-residu asam amino di binding pocket dan menyajikannya dalam bentuk
binary bitstrings, yang kemudian dibandingkan dengan binary bitstrings sidik jari interaksi pose asli ligan ko-kristal.
Hasil penelitian menunjukkan bahwa simulasi penambatan ulang dengan berbantukan PyPLIF memiliki kemampuan
jauh lebih baik dalam mereproduksi posisi asli ligan ko-kristal dibandingkan dengan simulasi penambatan ulang
dengan menggunakan fungsi penskoran bawaan asli aplikasi penambatan molekul yang digunakan. Dari 1000 kali
iterasi, simulasi penambatan ulang berbantukan PyPLIF mampu mereproduksi posisi asli ligan ko-kristal sebanyak
971 kali (lebih dari 95%) sementara simulasi penambatan ulang tanpa penskoran ulang dengan PyPLIF hanya
mampu mereproduksi sebanyak 500 kali (50%). Penelitian ini memberikan fondasi awal untuk konstruksi protokol
Penapisan Virtual Berbasis Struktur (PVBS) yang valid guna mengidentifikasi inhibitor COX-1.
Kata Kunci: PyPLIF; penskoran ulang; Penapisan Virtual Berbasis Struktur (PVBS); penambatan molekuler
INTRODUCTION
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs,
e.g. aspirin, indomethacin, and diclofenac) play an
important role by inhibiting cyclooxygenase (COX)
enzyme from converting arachidonic acid (AA) to
prostaglandin (PG) H [1-2]. This leads to the inhibition
of the inflammation processes [1]. COX consists of two
NOTE
Indo. J. Chem., 2013, 13 (3), 283 - 286
Muhammad Radifar et al.
284
Fig 1. Structure of 2-(1-[(4-chlorophenyl)carbonyl]-5-
methoxy-2-methyl-1H-indol-3-yl)-N-[(1R)-1-(hydroxyme-
thyl)propyl]acetamide (IMM) [9,15]
isoforms, which are cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2) [3-4]. It is believed that COX-
1 plays an important role in the anti-inflammatory
processes since inhibiting this enzyme can lead to
gastrointestinal (GI) toxicities while COX-2 in the pro-
inflammatory processes [2,4]. However, selective
inhibition COX-2 can lead to cardiovascular side effects
[2]. To avoid both the GI toxicities from selective COX-1
inhibition and the cardiovascular side effects from
selective COX-2 inhibition of the anti-inflammatory
agents, a new strategy involving discovery and
development dual COX-1/COX-2 inhibitors has been
proposed [5-6].
Discovery of dual COX-1/COX-2 inhibitors can be
more effective and efficient by employing valid Structure-
Based Virtual Screening (SBVS) protocols. Interestingly,
recent publications on the enhanced version (DUD-e) of
directory of useful decoys (DUD) as well as the original
version of DUD have retrospectively validated SBVS
protocols either to identify COX-1 or COX-2 inhibitors [7-
8]. The quality of SBVS protocols to discover COX-2
inhibitors are acceptable since the enrichment factor at
1% false positives (EF1%) value can reach more than 20
[7-8]. However, both [7-8] showed that the construction
of SBVS protocols to discover COX-1 inhibitors remains
challenging since the protocols resulted in the EF1%
values of less than 5 [7-8]. Recent attempts by
Istyastono [9] to initially construct and validate an SBVS
protocol to discover COX-1 inhibitors by redocking the
co-crystal ligand showed that the co-crystal ligand can
be docked in two possible poses with a 50:50 chance.
This information can be useful in the de novo design but
to have more confidence to employ the constructed
SBVS protocol further [10], the protocol should be able
to redock the co-crystal ligand correctly most of the time
[11]. Previous attempts to construct a valid SBVS
protocols to discover COX-1 inhibitors did not involve
rescoring processes by using protein-ligand interaction
fingerprints (PLIF) identification [7–9], which on the other
hand were reported could enhance the quality of SBVS
protocols [12-14]. Therefore, more attempts assisted by
PLIF identification for rescoring are needed to have a
valid SBVS protocol in order to identify COX-1
inhibitors since some high resolution COX-1 crystal
structures are recently publicly available [15-17].
The construction of SBVS protocols to identify
COX-1 inhibitors using PLANTS docking software
version 1.2 (PLANTS1.2) [18-19] was reported by
Istyastono [9]. These attempts incorporated iterative
procedures 1000 times to optimize the protocols [9].
Although the iterative optimization procedures were
able to obtain a docking protocol with an RMSD value
of 0.633 Å, the iterative procedures have suggested
two possibilities of the docked poses with a chance of
50-50 [9-10]. These indecisive protocols can mislead
the selection of the best pose in a virtual screening
campaign [10]. Further attempts by employing PyPLIF
[14] to identify PLIF as the rescoring functions to have
a better first step in the development of a good quality
SBVS protocol to identify COX-1 inhibitors are
presented in this article. These PyPLIF-assisted
redocking simulations could identify 971 correct poses
(more than 95%) out of 1000 redocking attempts.
METHODS
Materials
The docked poses from 1000 iterative redocking
simulations of of indomethacin-(R)-α-ethyl-etanolamide 
(IMM; Fig. 1) in the COX-1 binding site performed by
Istyastono [9], the output of the bind module of
PLANTS1.2 [18-19] performed by Istyastono [9] stored
as PLANTSactiveSiteResidues.mol2 used as the
binding site and the output of the splitpdb module of
SPORES [20] stored as ligand_IM8700_0.mol2 used
as the reference co-crystal pose were obtained from
previous works [9].
Computation details
PyPLIF [14] which was developed based on
protein-ligand interaction conventions [11] were used to
identify the PLIF of each docked pose and to calculate
the similarity to the PLIF of the co-crystal ligand by
using Tanimoto coefficient (Tc-PLIF) [14]. Instead of
based on the ChemPLP score [9,18], the best pose of
each redocking simulation was selected from the
highest Tc-PLIF value [14]. The RMSD values
calculations and pictures generations were then
performed using PyMOL (http://www.pymol.org/) [9,21].
All calculations and computational simulations were
performed on a Linux (Ubuntu 10.04 LTS Lucid Lynx)
machine with Intel® Xeon® Duo 5150 (@ 2.66 GHz) as
the processors and 1.00 GB of RAM.
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Fig 2. The RMSD values over 1000 iterations of the
PyPLIF-assisted re-docking simulations
Fig 3. The frequency distribution of the RMSD values
presented in a histogram
Fig 4. All PyPLIF-selected docking poses of the
reference ligand MIM aligned to the crystal structure
pose: The docking poses resulted in the protocol that
have RMSD value of < 2.0 Å (a) and the docking poses
resulted in the protocol that RMSD value of ≥ 2.0 Å (b).
The docked poses are presented in the lines mode,
while the crystal structure pose is presented in the sticks
mode. Hydrogens are not shown, carbon atoms are
presented in magenta and in cyan for the crystal
structure pose and the docking poses respectively,
chlorine atoms are presented in light green, nitrogen
atoms are presented in blue, and oxygen atoms are
presented in red
Procedure
PyPLIF [14] was subjected to each docked pose
obtained from previous works [9] by using
PLANTSactiveSiteResidues.mol2 as the binding pocket.
PyPLIF converted the PLIF into binary bitstrings and
calculated the similarity of the bitstrings to those
obtained from the PLIF of the co-crystal ligand resulted
in Tc-PLIF values. For each redocking simulation, the
docked pose with the highest Tc-PLIF was selected as
the best docked pose. The root mean square distances
(RMSD) value between the selected docked pose and
the pose of the co-crystal ligand was calculated using
rms_cur module in PyMOL [9]. The protocols were
considered as acceptable in reproducing the co-crystal
ligand pose if resulted in the RMSD value of less than
2.0 Å [11].
RESULT AND DISCUSSION
This research aimed to examine whether PyPLIF
as a rescoring strategy can increase the quality of the
validation initial step of the SBVS protocols to discover
COX-1 inhibitors which were built using PLANTS1.2 as
the docking software. In the previous attempts by [9]
showed that to reproduce the co-crystal IMM into the
binding pocket of COX-1 (prepared from the crystal
structure with pdb code of 2OYE [9,15] remains
challenging since Istyastono [9] could sample two
possible binding poses of the ligand with a chance of
50-50 instead of correctly reproduce the co-crystal
pose only. Although Istyastono [9] could offer the
opportunities to determine the important interactions
that lead to the optimization of COX-1 inhibitors in a de
novo design, the results of the previously developed
protocols reflected the indecisive nature of using the
default scoring function to identify the correct binding
pose of inhibitors to COX-1 binding pocket. The results
of using PyPLIF as the rescoring strategy are
presented in Fig. 2 and 3.
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By employing PyPLIF as the rescoring strategy, the
protocols increase the ability to reproduce the pose of
the co-crystal ligands from 50% out of 1000 iterative
runs to 97.1% (Fig. 2 and 3). Interestingly, different with
the previously published attempts [9], which showed
exactly similar binding poses for the rest 50%, by using
PyPLIF the rest of 2.9% showed binding poses diversity
(Fig. 4). The rescoring strategy used in this research has
remarkably increased the quality of the initial validation
of the SBVS protocols. Similar success stories in
employing PLIF identification to enhance the SBVS
protocols quality have been reported by [9-10,12-14,22].
Remarkably, PyPLIF used in this research was
published by [14] as an open source software under
GNU General Public License version 3 (GNU GPL v3)
that can be adapted for further or other purposes in the
drug design and discovery area [14,22].
The retrospective validation of these PyPLIF-
assisted SBVS protocols to discover COX-1 inhibitors
are being performed by using DUD-e datasets [8] and
are going to be evaluated prospectively by employing
ZINC database [23-24]. The quest to construct valid
SBVS protocols to identify COX-1 inhibitors is
challenging since some previous attempts resulted in
poor EF1% values [7-8]. Moreover, the availability of the
valid protocols will be beneficial not only to discover
COX-1 inhibitors, but also to discover selective COX-2
inhibitors or even dual COX-1/COX2 inhibitors [9,25].
CONCLUSION
The application of PLIF identification by employing
PyPLIF as the rescoring strategy increases the quality of
the initial step in the construction of valid SBVS
protocols employing PLANTS1.2 as the docking
software to identify COX-1 inhibitors.
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